• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab deruxtecan: Defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?

作者信息

Bartsch Rupert, Preusser Matthias

机构信息

Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria.

出版信息

Neuro Oncol. 2024 Dec 5;26(12):2157-2158. doi: 10.1093/neuonc/noae202.

DOI:10.1093/neuonc/noae202
PMID:39360612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11630533/
Abstract
摘要

相似文献

1
Trastuzumab deruxtecan: Defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?曲妥珠单抗德鲁昔单抗：能否为HER2阳性乳腺癌脑转移定义一种新的全身治疗标准？
Neuro Oncol. 2024 Dec 5;26(12):2157-2158. doi: 10.1093/neuonc/noae202.
2
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.使用安罗替尼和曲妥珠单抗德鲁昔单抗治疗HER2阳性乳腺癌脑转移：一例报告
Int J Womens Health. 2024 Jul 29;16:1277-1283. doi: 10.2147/IJWH.S472628. eCollection 2024.
3
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
4
Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康：在不可切除或转移性 HER2 阳性乳腺癌中的应用评价。
Target Oncol. 2023 May;18(3):463-470. doi: 10.1007/s11523-023-00971-9. Epub 2023 May 2.
5
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康偶联物（fam-trastuzumab deruxtecan-nxki）治疗 HER2 阳性乳腺癌的研究进展
Ann Pharmacother. 2021 Nov;55(11):1410-1418. doi: 10.1177/1060028021998320. Epub 2021 Feb 25.
6
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
7
Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: A Single-center Experience and Review of the Literature.曲妥珠单抗德鲁替康与放射治疗在HER2阳性和HER2低表达转移性乳腺癌中的联合应用：单中心经验及文献综述
Am J Clin Oncol. 2024 Dec 1;47(12):580-584. doi: 10.1097/COC.0000000000001135. Epub 2024 Jul 16.
8
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.TUXEDO-4：曲妥珠单抗-德曲妥珠单抗治疗伴有新发性或进展性脑转移的HER2低表达乳腺癌的II期研究。
Future Oncol. 2025 Apr;21(9):1065-1073. doi: 10.1080/14796694.2025.2470604. Epub 2025 Feb 28.
9
Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.曲妥珠单抗德鲁昔单抗治疗HER2阳性且伴有活跃脑转移的乳腺癌的三项研究的患者水平汇总分析结果。
ESMO Open. 2025 Jan;10(1):104092. doi: 10.1016/j.esmoop.2024.104092. Epub 2025 Jan 3.
10
Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis.人表皮生长因子2阳性乳腺癌脑转移患者的治疗选择：一项系统评价和荟萃分析
Front Oncol. 2023 Feb 20;13:1003565. doi: 10.3389/fonc.2023.1003565. eCollection 2023.

引用本文的文献

1
Drug treatment of breast cancer brain metastases: progress and challenges.乳腺癌脑转移的药物治疗：进展与挑战
Discov Oncol. 2025 Jun 7;16(1):1025. doi: 10.1007/s12672-025-02820-9.
2
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2025年更新版
Breast Care (Basel). 2025 Mar 8:1-12. doi: 10.1159/000545018.

本文引用的文献

1
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.曲妥珠单抗德鲁替康用于伴脑转移的人表皮生长因子受体2（HER2）阳性转移性乳腺癌患者的汇总分析。
Ann Oncol. 2024 Dec;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347. Epub 2024 Sep 5.
2
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.曲妥珠单抗-德曲妥珠单抗用于HER2阳性且伴有活动性脑转移的乳腺癌患者的II期TUXEDO-1试验的最终结果分析。
Neuro Oncol. 2024 Dec 5;26(12):2305-2315. doi: 10.1093/neuonc/noae123.
3
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
4
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2 阳性乳腺癌伴中枢神经系统转移患者：DEBBRAH 试验。
Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144.
5
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
6
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.脑转移瘤的治疗：美国临床肿瘤学会-神经肿瘤学会-美国放射肿瘤学会指南
J Clin Oncol. 2022 Feb 10;40(5):492-516. doi: 10.1200/JCO.21.02314. Epub 2021 Dec 21.
7
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.欧洲肿瘤内科学会转移性乳腺癌患者诊断、分期及治疗临床实践指南
Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19.
8
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.脑转移瘤患者的生存：诊断特异性分级预后评估更新的总结报告和资格系数的定义。
J Clin Oncol. 2020 Nov 10;38(32):3773-3784. doi: 10.1200/JCO.20.01255. Epub 2020 Sep 15.
9
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、曲妥珠单抗和卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.